Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia ...

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year ...

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

The PEACE-1 trial (NCT01957436) revealed that adding radiotherapy to standard of care (SOC) and abiraterone significantly ...

Thomas W. LeBlanc, MD, MA, discusses how existing challenges in treatment choices for low-risk myelodysplastic syndromes ...

Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant ...